At Imbria, we are using our deep understanding of energy metabolism to develop novel therapies designed to substantially improve the lives of patients with life-altering diseases. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy in disorders where energetic impairment is a fundamental contributor, including cardiovascular disease and specific inborn errors in metabolism.
...
At Imbria, we are using our deep understanding of energy metabolism to develop novel therapies designed to substantially improve the lives of patients with life-altering diseases. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy in disorders where energetic impairment is a fundamental contributor, including cardiovascular disease and specific inborn errors in metabolism.
Our lead program, IMB-101, is currently in Phase 2 clinical development in three indications: Hypertrophic cardiomyopathy, stable angina, and type 2 diabetes at risk for diabetic cardiomyopathy.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.